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for only about 3% of all patients with this disease. Most infections are associated with the
use of intravenous drugs. Patients with P. aeruginosa-related IE who do not use intravenous
drugs are extremely rare. We carried out a review of the literature to identify the nature
and risk factors of this disease.
Methods: Patients with IE reported between 1993 and 2013 were reviewed by searching the
Medline database using the keywords “endocarditis” and “Pseudomonas aeruginosa”. All of
the patients included met the definition of the modified Duke criteria.
Results: Twenty-seven patients in 22 reports were reviewed. IE associated with health care
accounted for 20 patients (74%). The mean age of the patients was 53.4 years and there
was a predominance of men (81.5%). Native valve endocarditis was seen in 20 (74.1%) pa-
tients. Surgery for infection control was performed in 15 (55.6%) patients and the mortality
rate in patients who underwent surgery was 33.3% (five patients). A relapse of IE aftert of Pediatrics, Kaohsiung Veterans General Hospital, Number 386, Dazhong First Road, Zuoying
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Pseudomonus aeruginosa infective endocarditis 517adequate treatment was seen in nine (33.3%) patients. The mortality rate in all 27 patients
was 28.6% (2/7) for those with community-acquired IE and 40% (8/20) for those with IE asso-
ciated with health care. Univariate analysis showed a higher mortality rate in patients aged
>60 years and in those whose source of endocarditis was related to a prosthetic device.
Conclusion: P. aeruginosa endocarditis has substantial morbidity and mortality. It is charac-
terized by easy relapse and is highly associated with prosthetic devices.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Infective endocarditis (IE) caused by Pseudomonas aerugi-
nosa is infrequent, accounting for approximately 3% of all
patients with IE.1 About 90% of patients with IE related to P.
aeruginosa use intravenous drugs.2 Patients with IE related
to P. aeruginosa who do not use intravenous drugs are
extremely rare and only a few patient reports and brief
case series have been published. Most of these reports
reveal that IE caused by P. aeruginosa may be very
aggressive and has a high rate of mortality.
To provide more insights into the clinical presentations
of this disease and to evaluate the prognostic factors, a
literature review covering the period 1993e2013 was con-
ducted, including one recent patient treated in Kaohsiung
Veterans General Hospital, Kaohsiung, Taiwan.
Materials and methods
A systematic Medline review covering the period from
January 1, 1993 to June 30, 2013 was conducted using the
search terms “endocarditis” and “Pseudomonas aerugi-
nosa”. The search focused only on articles published in
English. Two clinicians read the articles independently and
decided which articles should be included in the review.
The articles were included if the patient reported met
the modified Duke criteria of IE with isolates of P. aerugi-
nosa.3 These articles contained specific information on
clinical, therapeutic, and outcome variables. For each pa-
tient reported, the following variables were recorded: de-
mographic data (age and sex), clinical data (site and type of
valves affected, echocardiography findings, entry site of
the infection, any previous history of invasive procedures,
and a relapse of the IE after completion of treatment), type
of treatment (antimicrobial treatment with or without
surgery), and outcome (death or recovery). A recent inva-
sive procedure was defined as an intravascular device-
related procedure within 1 year of the episode of P. aeru-
ginosa IE, such as prosthetic valve replacement, central
venous catheter insertion, an arterio-venous graft opera-
tion, cardiac catheterization, pacemaker insertion, and
major surgery (i.e., open heart surgery), renal trans-
plantation, biliary prosthesis implantation, and invasive
urinary procedures such as cystoscopy.
IE associated with health care was defined as either
nosocomial infection or non-nosocomial infection associ-
ated with health care.4 Nosocomial infection was defined as
IE developing in a patient hospitalized for>48 hours prior tothe onset of the symptoms and signs of IE. Non-nosocomial
infection associated with health care was defined as IE
diagnosed within 48 hours of admission as an outpatient
with extensive health care contact including any of the
following criteria: (1) the patient had received intravenous
treatment, wound care, or specialized nursing care at home
within 30 days prior to the onset of P. aeruginosa IE; (2) the
patient had attended a hospital or hemodialysis clinic or
received intravenous chemotherapy within 30 days prior to
the onset of P. aeruginosa IE; (3) the patient was hospital-
ized in an acute care hospital for 2 days in the 90 days
prior to the onset of P. aeruginosa IE; or (4) the patient
resided in a nursing home or long-term care facility.4,5
Community-acquired IE that was not related to intra-
venous drug use was defined as IE diagnosed at the time of
admission (or within 48 hours of admission) in a patient not
fulfilling the criteria for infection associated with health
care and with no history of using intravenous drugs.
Immunocompromised patients were defined as patients
who were receiving long-term immunosuppressive treat-
ment, or who had hematological disease as a result of
chemotherapy. A relapse of IE after adequate treatment is
defined as a new episode caused by P. aeruginosa within 6
months of the first episode of P. aeruginosa IE.
Statistical analysis
SPSS version 17.0 (SPSS Inc., Chicago, IL, USA) was used for
all statistical analyses. The mean, standard deviation,
median, and range were calculated for continuous vari-
ables. The c2 test and Fisher’s exact test were used to
determine significant differences between groups with
categorical variables. Univariate analyses were used to
determine the association between potential risk factors
and mortality. Statistical significance was set at p  0.05.
Results
In this comprehensive review of the literature from 1993 to
2013, 27 patients with P. aeruginosa IE were identified from
22 articles.6e27 All 27 patients met the modified Duke
criteria and none of the patients used intravenous drugs.
Community-acquired P. aeruginosa IE accounted for seven
patients (25.9%) and P. aeruginosa IE associated with health
care accounted for 20 patients (74.1%).
The clinical characteristics of the reported patients are
given in Table 1. The patients with community-acquired IE
had a mean age of 50.9 years and those with IE associated
Table 1 Clinical characteristics of 27 patients with Pseudomonas aeruginosa infective endocarditis
Variable N (%) (n Z 27) N (%) with
community-acquired
infection (n Z 7)
N (%) with infection
associated with health
care (n Z 20)
p
Age(y) 53.4  16.4 (216.3) 50.9  15.7 (21e66) 54.4  16.9 (21e83) 0.64
Age 60 y 11 (40.7) 3 (42.9) 8 (40.0) >0.99
Male sex 22 (81.5) 5 (71.4) 17 (85.0) 0.58
History of congenital heart disease 3 (11.1) 2 (28.6) 1 (5.0) 0.16
Known site of entry of infection 19 (70.4) 2 (28.6) 17 (85.0) 0.01 *
Diabetes mellitus 5 (18.5) 2 (28.6) 3 (15.0) 0.58
Hemodialysis 3 (11.1) 0 (0) 3 (15.0) 0.55
Immunocompromised patient 5 (18.5) 0 (0) 5 (25.0) 0.28
Location
Left-side 17 (63.0) 4 (57.1) 13 (65.0) d
Mitral valve 8 (29.6) 3 (42.9) 5 (25.0) d
Aortic valve 8 (29.6) 0 (0) 8 (40.0) d
Both 1 (3.7) 1 (14.3) 0 (0) d
Right-side 7 (25.9) 2 (28.6) 5 (25.0) d
Tricuspid valve 1 (3.7) 0 (0) 1 (5.0) d
Pulmonary valve 3 (11.1) 1 (14.3) 2 (10.0) d
Both valves 3 (11.1) 1 (14.3) 2 (10.0) d
Pacemaker 2 (7.4) 0 (0) 2 (10.0) d
Patent foramen ovule 1 (3.7) 1 (14.3) 0 (0) d
Bacterial growth seen on echocardiography 25 (92.6) 7 (100.0) 18 (90.0) >0.99
Echocardiography
Transthoracic echocardiography 8 (33.3) 2 (28.6) 6 (30.0) d
Transesophageal echocardiography 17 (66.7) 5 (71.4) 12 (60.0) d
Surgery 15 (55.6) 4 (57.1) 11 (55.0) >0.99
Native valve involvement 20 (76.9) 5 (71.4) 15 (75.0) >0.99
Recent history of invasive procedure 15 (56.6) 1 (14.3) 9 (45.0) 0.20
Related to prosthetic device 11 (40.7) 1 (14.3) 10 (50.0) 0.18
Complication 19 (70.4) 6 (85.7) 13 (65.0) 0.63
Embolization 8 (29.6) 2 (28.6) 6 (30.0) >0.99
Congestive heart failure 10 (37.0) 3 (42.9) 7 (35.0) >0.99
Intracardiac abscess 4 (14.8) 2 (28.6) 2 (10.0) 0.27
Relapse after adequate treatment 9 (33.3) 2 (28.6) 7 (35.0) >0.99
Mortality 10 (37.0) 2 (28.6) 8 (40.0) 0.68
Data are presented as mean  standard deviation (range) or n (%).
* p < 0.05.
518 T.-I Lin et al.with health care had a mean age of 54.4 years. Five (71.4%)
patients with community-acquired IE were men and 17
(85%) patients with IE associated with health care were
men. Seventeen (85%) patients with IE associated with
health care had a known portal of entry, compared with
only two (28.6%) patients with community-acquired IE.
Comorbidities occurred in six (85.7%) patients with
community-acquired IE and in 14 (70%) patients with IE
associated with health care. Nine (45%) patients with IE
associated with health care had a history of a recent
invasive procedure, which was only found in one (14.3%)
patient with community-acquired IE. Infection of the native
valve occurred in five (71.4%) patients with community-
acquired IE and in 15 (75%) patients with IE associated
with health care. Left-sided IE occurred in four (57.1%)
patients with community-acquired IE and 13 (65%) of pa-
tients with IE associated with health care.
Of the 27 patients who received echocardiography, 25
(92.6%) had detectable bacterial growth. Surgery forinfection control was required in four (57.1%) patients with
community-acquired IE and in 11 (55%) patients with IE
associated with health care. A relapse of IE after adequate
treatment occurred in two (28.6%) patients with
community-acquired IE and in seven (35%) patients with IE
associated with health care. The overall mortality of P.
aeruginosa IE was 28.6% in community-acquired IE and 40%
in IE associated with health care. Compared with
community-acquired P. aeruginosa IE, only the known site
of entry of the infection was significantly higher in IE
associated with health care in the univariate analysis.
The mortalities and survival of patients with P. aerugi-
nosa IE were compared (Table 2). In univariate analysis, age
>60 years and a prosthetic device as the source of IE were
factors that had significant association with mortality. Pa-
tients who relapsed and those who did not relapse with
P. aeruginosa IE were compared (Table 3). In univariate
analysis, only mortality was significantly higher in patients
who relapsed.
Table 2 Comparisons between patients who died and surviving patients with Pseudomonas aeruginosa infective endocarditis
Variable Total no. of patients N (%) of patients who died OR (95% CI) p
Age 60 y 11 7 (63.6) 7.58 (1.31.53.92) 0.04 *
Male sex 22 9 (40.9) 0.36 (0.03.3.79) 0.62
IE associated with health care 7 2 (28.6) 0.60 (0.09.6.89) 0.68
Diabetes mellitus 5 2 (40.0) 1.17 (0.16e8.53) >0.99
Hemodialysis 3 0 (0) d d
Congenital heart disease 3 1 (33.3) 0.83 (0.07.80.55) >0.99
Immunocompromised patient 5 3 (60.0) 3.21 (0.43e23.79) 0.33
Surgery for infection control 15 5 (33.3) 0.70 (0.15.7.37) 0.71
Prosthetic valve 6 4 (66.7) 4.67 (0.67.62.74) 0.16
Bacterial growth seen on echocardiography 25 9 (36.0) 0.56 (0.03.50.11) >0.99
Right-sided vegetation 7 2 (28.6) 0.60 (0.09.6.17) >0.99
Prosthetic device-related infection 16 9 (56.3) 12.88 (1.312.25.78) 0.02 *
Previous open heart surgery 9 4 (44.4) 1.60 (0.31.6.25) 0.68
History of recent invasive procedure 10 4 (40.0) 1.22 (0.24e6.11) >0.99
Complications 19 9 (47.3) 6.30 (0.64e61.63) 0.19
Congestive heart failure 10 6 (60.0) 4.88 (0.90e26.42) 0.10
Intracardiac abscess 4 3 (75.0) 6.86 (0.60e77.98) 0.13
Embolization 7 2 (28.6) 0.60 (0.09e0.89) 0.68
OR Z odds ratio; CI Z confidence interval.
*p < 0.05.
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P. aeruginosa IE was first reported in 1899 by Reyes et al.28
It belongs to the group of non-HACEK gram-negative
bacteria (species other than Haemophilus species, Actino-
bacillus actinomycetemcomitans, Cardiobacterium homi-
nis, Eikenella corrodens, or Kingella spp.) that cause IE.
About 90% of patients with P. aeruginosa IE use intravenous
drugs2; however, health care-associated infection may beTable 3 Comparisons between relapse and non-relapse patient
Variable N (%) of patien
Age 60 (y) 5 (45.5)
Male 8 (36.4)
Health care-associated 7 (35.0)
Diabetes mellitus 2 (40.0)
Hemodialysis 0 (0)
Congenital heart disease 2 (66.7)
Immunocompromised patient 1 (20.0)
Prosthetic valve 3 (50.0)
Bacterial growth on echocardiography 8 (32.0)
Right-sided vegetation 3 (42.9)
Prosthetic device-related 5 (45.5)
Previous open heart surgery 5 (55.6)
Recent invasive procedure history 3 (30.0)
Surgery for infection control 5 (33.3)
Complication 8 (42.1)
Congestive heart failure 5 (50.0)
Intracardiac abscess 3 (60.0)
Embolization 3 (42.9)
Mortality 7 (70.0)
OR Z odds ratio; CI Z confidence interval.
* p < 0.05.another important risk factor in P. aeruginosa IE. The study
of Morpeth et al29 emphasized the importance of the as-
sociation between health care contact and non-HACEK
gram-negative bacillus IE. In their study, more than half
of the patients with non-HACEK gram-negative bacillus IE
had infection associated with health care (57%) and
implanted endovascular devices were frequently associated
with non-HACEK gram-negative bacillus IE (p < 0.05). In this
study, infection associated with health care in patients withs of Pseudomonas aeruginosa infective endocarditis
ts relapsing OR (95% CI) p
2.50 (0.49.52.89) 0.41
0.44 (0.41.4.62) 0.64
0.74 (0.11.7.87) >0.99
1.43 (0.19.40.57) >0.99
d d
4.68 (0.38.62.63) 0.25
0.43 (0.04.4.62) 0.64
2.33 (0.36.35.05) 0.63
0.47 (0.03.4.52) >0.99
1.38 (0.23.3.30) >0.99
2.50 (0.49.52.89) 0.41
4.38 (0.78.34.47) 0.11
0.79 (0.15.7.21) >0.99
1.00 (0.20.0.00) >0.99
5.09 (0.52.00.00) 0.20
3.25 (0.61.27.28) 0.22
4.00 (0.53.00.16) 0.29
1.75 (0.30.7.00) 0.65
17.5 (2.377.29.51) <0.05 *
520 T.-I Lin et al.P. aeruginosa IE who did not use intravenous drugs
accounted for 20 (74.1%) of 27 patients.
In this study, patients with P. aeruginosa IE with a history
of a previous invasive procedure accounted for 15 (55.6%)
of 27 patients. IE related to a prosthetic device accounted
for 11 (40.7%) patients. In a study of 1779 patients, a pre-
sumed intravascular device source accounted 28.4% of pa-
tients with Staphylococcus aureus IE.4 Patients with IE
related to a prosthetic device had a higher mortality rate in
this review (p < 0.05). Thus device-related infection is an
important risk factor for mortality in P. aeruginosa IE.
Although staphylococci account for the majority of device-
related infections and either coagulase-negative staphylo-
cocci or S. aureus is the most common pathogen identi-
fied,30 this review suggests that P. aeruginosa must still be
considered in device-related IE.
In a cohort study with 1874 patients, repeat IE occurred
in 4.8%. Among these, 81% had a new infection and 19%
were presumed to be relapsed patients. S. aureus was the
major cause of repeated IE (41%); the relapse rate of S.
aureus in this cohort study was 2.9% (15/519).31 In the
current review, 33% (9/27) of patients had a relapse of IE
and had a significant difference in mortality (p < 0.05).
These suggest that P. aeruginosa IE may have a higher rate
of relapse than other microorganisms and a higher mortality
if patients have a presumed relapse.
Previous studies have identified risk factors for repeated
IE such as intravenous drug use, congenital and rheumatic
heart disease, prior episode(s) of endocarditis, chronic
dialysis, male sex, and older age (>65 years).31 In the
present review, analysis of the risk factors and outcome
between relapsed and non-relapsed patients showed only
one significant difference in mortality (Table 3).
In the present review, P. aeruginosa IE in patients who
did not use intravenous drugs usually developed in male
patients with an age of about 50 years. Most patients ac-
quired the infection through an invasive procedure (14.3%
in community-acquired IE; 45% in IE associated with health
care), which is similar to that of S. aureus IE, the leading
current cause of IE. In the study by Fowler et al,4 a recent
invasive procedure accounted for 9.6% of community-
acquired S. aureus IE in patients who did not use intrave-
nous drugs and 48.6% of patients with S. aureus IE associ-
ated with health care.
In the present review, P. aeruginosa more frequently
invaded the left-sided valves, with mitral or aortic valve
involvement, than the right-sided valves (55% vs. 33%). Most
of infections involved the native valve (76.9%). In this
study, 55.6% (15/27) of patients underwent valve replace-
ment or other open heart surgery for infection control. Four
series showed that rates of valve replacement in IE caused
by all pathogens ranged from 15% to 45%.1,32e34 The rate of
surgery in patients with S. aureus IE in a study of 1779
patients was 37.8%,4 indicating that P. aeruginosa IE might
have a higher rate of surgery. Although cardiac valve sur-
gery was recommended for non-HACEK gram-negative ba-
cillus IE, which included P. aeruginosa IE,35 the mortality
rate in this review did not reveal any significant difference
between surgical and non-surgical treatment.
Congenital heart disease (CHD) is the leading risk factor
for pediatric IE in developing countries after the decline of
rheumatic heart disease.36 In a large review article, theleading microorganism causing CHD-related IE was Strep-
tococcus spp. (44%), Staphylococcus spp. (27%), and Gram-
negative HACEK group bacteria (16%).36 P. aeruginosa is a
rare pathogen for CHD-related IE. In this review, three
patients had a history of CHD and none of the three un-
derwent open heart surgery for CHD correction. One was
successfully treated with antimicrobial treatment alone.
The other two patients underwent cardiac surgery for IE
control and one of them died due to a repeat episode of IE.
The overall mortality in CHD-related IE had decreased to
10% in the 1990s due to improvements in diagnosis, anti-
microbial treatment, cardiac surgery, and interventional
catheter treatment.36 In a study with 216 patients, surgical
intervention was still a predictive factor for a lower rate of
in-hospital mortality in CHD-related IE.37 However, most
series had few patients of CHD-related P. aeruginosa IE,
thus warranting further study and analysis in terms of sur-
gical indication and outcomes.
Complications of P. aeruginosa IE include heart failure
and arterial emboli involving the brain, spleen, and kid-
neys.38 Cerebritis, brain abscesses, and mycotic aneurysms
may also occur.39 In this review, one patient had meningi-
tis26 and another had endophthalmitis.15 The rate of com-
plications was 85.7% (6/7 patients) in community-acquired
IE and 65% (13/20 patients) in IE associated with health
care, which are relatively higher than that of S. aureus IE
(range 12.7e8.9%).4 Patients with complications also have
higher mortality rates (47% vs. 12.5%).
In this study, the mortality rate associated with P. aer-
uginosa IE was 28.6% in community-acquired IE and 40% in IE
associated with health care. In a previous series, the overall
mortality ranged from 18.0% to 24.6%.1,32e34 In a study of S.
aureus IE, the mortality_ENREF_35 rate was 21.1% in IE not
associated with intravenous drug use and 29.4% in IE asso-
ciated with health care.4 Compared with these results, the
mortality of patients with P. aeruginosa IE was similar in
primary community-acquired IE and slightly higher in IE
associated with health care. Another series with a small
number of patients indicated that P. aeruginosa IE associ-
ated with intravenous drug use had a mortality rate of 10%
(1/10).40 In the current review, the mortality of
community-acquired P. aeruginosa IE not associated with
intravenous drug use (28.6%) appeared to be similar to that
of P. aeruginosa IE associated with intravenous drug use.
However, further analysis should be performed to verify
this.
There are some limitations in this study. The main
source of information was patients reported in the litera-
ture, which might have significant selection bias for a
higher severity, more complicated course, and poorer
outcome. An individual investigator’s report cannot be
standardized for the patient variables and a bias may also
exist. Some patients who may be considered candidates for
surgery may have been excluded from surgical options due
to their poor condition. Certain subgroups of a small num-
ber of patients may produce type II errors. There are
missing data in these literature reports, include the
severity of disease, adequacy of the antibiotic regimen,
adequate dosage and duration of the antibiotic regimen,
size of bacterial growth, indication for surgery, and sus-
ceptibility data of P. aeruginosa. The patient numbers in
this study are too small to draw a significant conclusion.
Pseudomonus aeruginosa infective endocarditis 521In conclusion, P. aeruginosa IE not related to intravenous
drug use is rare, but is a very aggressive disease. It has the
characteristic of easy relapse and is highly associated with
the use of a prosthetic device. In the future, if more series
reports are published, there should be sufficient patients
for a more detailed analysis.
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